Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow grows to $4K
Q1 FY2026 depreciation & amortization was $4K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was -$102K. Over 3 fiscal years it compounded at -43.3% a year.
Context
- Depreciation & amortization amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $4K or moves back toward the trailing-twelve-month quarterly average of -$25.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 6K USD
- Year-over-year change
- -25.0%
- 4-year CAGR
- -38.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6K | -25.0% |
| FY2024 | 2024-12-31 | 8K | -33.3% |
| FY2023 | 2023-12-31 | 12K | -63.6% |
| FY2022 | 2022-12-31 | 33K | -23.3% |
| FY2021 | 2021-12-31 | 43K | — |
Depreciation & Amortization vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 depreciation & amortization of $102K is the smallest of the 11 companies compared; the peer median is $5.46M.
- Its year-over-year change of -2140.0% is the lowest of 11, against a peer median of -12.5%.
- Depreciation & amortization amounts to 0.0% of revenue for SNDX, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $10.17M | -10.7% | +6.1% | 9.7% | |
| LTM Jun 2026 | $10M | +0.0% | +18.6% | 8.5% | |
| LTM Sep 2026 | $9.03M | -29.4% | -2.5% | 3.4% | |
| LTM Mar 2026 | $6.94M | -7.1% | -22.5% | 4.4% | |
| LTM Dec 2025 | $3.98M | +18.5% | +17.7% | — | |
| LTM Mar 2026 | $1.19M | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $1.03M | -39.0% | -38.3% | 2.9% | |
| LTM Jun 2026 | $666K | -163.6% | +106.0% | 0.4% | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $102K | -2140.0% | -43.3% | 0.0% | |
| Peer median (excluding SNDX) | $5.46M | -12.5% | +12.9% | 3.4% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.